NASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis $2.55 +0.09 (+3.66%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Genelux Stock (NASDAQ:GNLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genelux alerts:Sign Up Key Stats Today's Range$2.40▼$2.5750-Day Range$1.98▼$3.3352-Week Range$1.60▼$16.60Volume194,751 shsAverage Volume183,587 shsMarket Capitalization$88.08 millionP/E RatioN/ADividend YieldN/APrice Target$18.25Consensus RatingBuy Company OverviewGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Read More… Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Genelux Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks27th Percentile Overall ScoreGNLX MarketRank™: Genelux scored higher than 27% of companies evaluated by MarketBeat, and ranked 823rd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 4 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.88) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.15% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Genelux has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.15% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Genelux has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.56 News SentimentGenelux has a news sentiment score of -0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Genelux this week, compared to 1 article on an average week.Search Interest6 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $736,831.00 in company stock.Percentage Held by InsidersOnly 9.30% of the stock of Genelux is held by insiders.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address GNLX Stock News HeadlinesGenelux Corp’s Strategic Advances in Cancer Trials Position GNLX as a Promising InvestmentNovember 17, 2024 | markets.businessinsider.comThese 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say AnalystsNovember 15, 2024 | finance.yahoo.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 22, 2024 | Crypto 101 Media (Ad)Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business UpdatesNovember 14, 2024 | markets.businessinsider.comGenelux Corp. Releases New Corporate PresentationNovember 9, 2024 | markets.businessinsider.comGenelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comIndividual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as wellOctober 31, 2024 | finance.yahoo.comGenelux initiated with a Buy at GuggenheimOctober 30, 2024 | markets.businessinsider.comSee More Headlines GNLX Stock Analysis - Frequently Asked Questions How have GNLX shares performed this year? Genelux's stock was trading at $14.01 on January 1st, 2024. Since then, GNLX stock has decreased by 81.8% and is now trading at $2.55. View the best growth stocks for 2024 here. When did Genelux IPO? Genelux (GNLX) raised $16 million in an initial public offering on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. Who are Genelux's major shareholders? Top institutional investors of Genelux include Geode Capital Management LLC (0.92%), LifeSteps Financial Inc. (0.23%), Exchange Traded Concepts LLC (0.19%) and Miracle Mile Advisors LLC (0.12%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genelux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$18.25 High Stock Price Target$30.00 Low Stock Price Target$8.00 Potential Upside/Downside+615.7%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax Margin-345,749.97% Return on Equity-105.05% Return on Assets-80.16% Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual Sales$170,000.00 Price / Sales518.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book2.66Miscellaneous Outstanding Shares34,540,000Free Float31,326,000Market Cap$88.08 million OptionableNot Optionable Beta-1.85 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:GNLX) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored25X predicted for “Amazon Coin” – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.